VANCOUVER, BC, Sept. 5, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces, further to its news release dated August 27, 2025, the consolidation of its common shares ("Common Shares") on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the "Consolidation").
The Company anticipates its Common Shares will commence trading on a post-Consolidation basis on the Canadian Securities Exchange (the "CSE") at market open on September 11, 2025. The new CUSIP number for the post-Consolidation Common Shares will be 09076M200 and the new ISIN number will be CA09076M2004. The name of the Company and trading symbol will remain the same after the Consolidation.
The Company currently has 293,425,203 Common Shares issued and outstanding. Following the Consolidation, the Company expects to have 29,342,496 Common Shares issued and outstanding, subject to any rounding variance. No fractional Common Shares will be issued as a result of the Consolidation. Any fractional Common Shares resulting from the Consolidation will be rounded up in the case of a fractional interest that is one-half (1/2) of a Common Share or greater, or rounded down in the case of a fractional interest that is less than one-half (1/2) of a Common Share, to the nearest whole number of Common Shares, and no cash consideration will be paid in respect of fractional Common Shares rounded down to the nearest whole Common Share. With the exception of the Debenture Warrants (as defined in the Company's news release dated August 27, 2025), the exercise price and number of Common Shares issuable upon the exercise of any outstanding securities convertible into Common Shares will be proportionately adjusted to reflect the Consolidation.
A letter of transmittal with respect to the Consolidation will be mailed to all registered shareholders of the Company holding physical certificates. All registered shareholders with physical certificates will be required to send their certificates representing pre-Consolidation Common Shares along with a completed letter of transmittal to the Company's transfer agent, Odyssey Trust Company, in accordance with the instructions provided in the letter of transmittal. A copy of the letter of transmittal will be posted on the Company's profile on SEDAR+ at www.sedarplus.ca.
Shareholders of the Company without physical share certificates do not need to take any action with respect to the Consolidation, as they will automatically receive a new DRS advice representing the post-Consolidation Common Shares.
Pursuant to the provisions of the Business Corporations Act (British Columbia) and the Articles of the Company, the Consolidation was approved by way of resolutions passed by the board of directors of the Company. The Consolidation and the date the post-Consolidation Common Shares commence trading on the CSE remain subject to the approval of the CSE and a bulletin will be issued by the CSE upon acceptance.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and its HapTenix® tumor cell construct platform, for treating cancers, infectious diseases, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum-resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix® 'neoantigen' tumor cell construct platform for refractory late-stage ovarian cancer.
BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin, Chief Executive Officer
Phone: +1 740 358 0555
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Revolutionizing treatment delivery